FOLH1 and prostate carcinoma: These findings suggest that the addition of antibodies or CARs targeting PSMA or EGFR may augment the ability of p50-IMC to induce a T cell response and increase efficacy against prostate cancer in patients not only by increasing the numbers of p50-IMC in the tumors, but also by enhancing phagocytosis of tumor cells.